Gemcitabine Current Events | Page 2

Gemcitabine Current Events, Gemcitabine News Articles.
Sort By: Most Viewed | Most Recent
Page 2 of 6 | 208 Results
New treatment option studied for bladder cancer
A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia. (2007-10-29)

U of M researchers identify 2 FDA approved drugs that may fight HIV
Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV. The two drugs, decitabine and gemcitabine -- both FDA approved and currently used in pre-cancer and cancer therapy -- were found to eliminate HIV infection in the mouse model by causing the virus to mutate itself to death -- an outcome researchers dubbed (2010-08-20)

Nanoparticle drug delivery technique shows promise for treating pancreatic cancer
Veterans Affairs researchers have designed a new way to deliver pancreatic cancer drugs that could make fighting the disease much easier. (2021-01-28)

New treatment for pancreatic cancer allows life-saving surgery
A new treatment for pancreatic cancer developed by clinical researchers of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center substantially reduces the size of tumors and lowers the risk of local recurrence of the disease. (2005-12-06)

Receiving chemotherapy following removal of type of cancer near pancreas may improve survival
Patients who had surgery for periampullary cancer (a variety of types of cancer that are located in and near the head of the pancreas, including an area called the ampulla where the bile duct joins up with the pancreatic duct to empty their secretions into the upper small intestine) and received chemotherapy had a statistically significant survival benefit, compared to patients who did not receive chemotherapy, after adjusting for prognostic variables, according to a study in the July 11 issue of JAMA. (2012-07-10)

Switch to metronomic therapy could offer new treatment option for patients with advanced kidney cancer
A new multi-targeted (2010-02-15)

Pancreatic cancer patient survival 'significantly higher' with nab-paclitaxel, says TGen-led study
By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute and Scottsdale Healthcare, published today by The New England Journal of Medicine. (2013-10-16)

Study evaluates efficacy and safety of pancreatic cancer treatment
In a new study published in the Journal of Clinical Oncology, Manuel Hidalgo, MD, PhD, and colleagues conducted a phase I/II trial designed to evaluate the efficacy and safety of nab-paclitaxel given in combination with gemcitabine in patients with pancreatic cancer and reduced health status. (2018-12-12)

Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients reports in the Annals of Oncology. (2004-01-12)

The effective chemoradiotherapy method for pancreatic cancer
In the present study, the retrospective analysis of chemoradiotherapy for locally advanced pancreatic cancer was performed, utilizing gemcitabine as a radiation sensitizer administered twice weekly at a dose of 40 mg/m2. The median survival was 15.0 months and the overall 1-year survival rate was 60%, while the median progression- free survival was 8 months. Patients developing liver metastases had worse prognosis. We might need another strategy for the chemoradiotherapy for those patients. (2008-09-19)

UIC conducts phase I drug study for advanced pancreatic cancer
UIC researchers are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer. (2014-06-03)

Chemotherapy trial proves the worth of including elderly patients in clinical trials
Doctors should be encouraged to include many more elderly people in clinical trials than they do at present, Dr Olavo Feher told the 3rd European Breast Cancer Conference in Barcelona today (Wednesday 20 March). Dr Feher, attending physician at the Hospital do Cancer in Sao Paulo, Brazil, said that the elderly were under-represented in clinical trials for cancer treatments, yet his research showed that useful results could be obtained if they were included in trials. (2002-03-20)

Potential cancer therapy may boost immune response
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators. (2020-12-07)

Study finds CT scans predict chemotherapy response in pancreatic cancer
Computed tomography scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from the University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment. (2014-03-11)

Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs. (2014-05-30)

Necitumumab in NSCLC: Indication of minor added benefit for patients with metastases
In metastatic NSCLC, there is an advantage in overall survival as well as disadvantages in side effects. No conclusions are possible on locally advanced non-metastatic NSCLC. (2016-07-04)

Certain factors may predict lung cancer patients' response to chemotherapy
In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis. (2018-01-10)

Chemotherapy with chemoradiation for pancreatic cancer has small survival benefit
The addition of the drug gemcitabine with chemoradiation for the treatment of patients who had surgery for pancreatic cancer was associated with a survival benefit, although this improvement was not statistically significant, according to a study in the March 5 issue of JAMA. (2008-03-04)

New drug achieves pancreatic cancer tumor remission and prevents recurrence
Pancreatic cancer remains one of the deadliest cancers, but researchers may have found a combination therapy to reduce cancer stem cells and stop pancreatic cancer growth. Results will be presented at the American Association for Cancer Research 100th Annual Meeting 2009. (2009-04-19)

Patients with EGFR expressing NSCLC benefit most from necitumumab added to chemotherapy
Patients with epidermal growth factor receptor expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference 2016 in Geneva, Switzerland. (2016-04-15)

New drug extends lung cancer survival 22 percent, UC Davis Cancer Center researchers report
Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolonged survival in patients with advanced non-small cell lung cancer. Results of the phase II trial, led by UC Davis Cancer Center researchers, were reported today at the annual meeting of the American Society of Clinical Oncology. (2006-06-03)

Researchers find new chemotherapy combination shows promise in endometrial cancer
Researchers from the University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients. (2010-03-17)

UAB study shows investigational drug may treat biliary cancers
Laboratory studies by University of Alabama at Birmingham researchers have shown that the investigational drug triphendiol causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments. (2008-04-15)

IDIBELL researchers successfully test a new combination therapy in sarcomas
Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. (2018-01-16)

Adult cancer drugs show promise against an aggressive childhood brain tumor
The quest to improve survival of children with a high-risk brain tumor has led St. Jude Children's Research Hospital investigators to two drugs already used to treat adults with breast, pancreatic, lung and other cancers. The study was published today online ahead of print in the journal Cancer Cell. (2014-03-27)

Wild berry extract may strengthen effectiveness of pancreatic cancer drug
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology. (2014-09-17)

Avantogen and Innovate announce ASCO abstracts
Avantogen Limited ( (2006-06-08)

Allergy drug slows pancreatic tumor growth in preclinical studies
An anti-allergy drug in use for more than 40 years significantly reduced tumor growth in animal models of human pancreatic cancer and also increased the effectiveness of standard chemotherapy, say researchers at the University of Texas M. D. Anderson Cancer Center. (2006-12-19)

Gene therapy improves gemcitabine effects in experimental glioma model
Attempts to improve the chemotherapeutic efficacy and radiotherapy-sensitivity of the anticancer agent, gemcitabine, using gene therapy have yielded interesting results in preclinical glioma models presented at the 13th European Cancer Conference (ECCO). (2005-10-31)

Study finds new way to make chemotherapy more effective against pancreatic cancer
Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs. A Mayo Clinic-led study published today opens a promising new front in that battle. (2019-09-18)

Drug with new approach on impeding DNA repair shows promise in first clinical trial
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer. (2020-06-15)

New biomarker may predict which pancreatic cancer patients respond to CD40 immunotherapy
Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight. (2021-02-04)

New drug candidate prolongs the lives of pancreatic cancer patients
The new drug compound Salirasib, developed at Tel Aviv University, has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it. (2009-07-20)

TGen Physician-in-Chief Dr. Daniel Von Hoff inducted today into Joshua Lederberg Society
Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute, will be inducted today into the Joshua Lederberg Society for his work in developing the drug Abraxane for advanced pancreatic cancer patients. (2014-02-13)

TGen, Scottsdale Healthcare study shows drug combination extends pancreatic cancer patient survival
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. (2013-01-22)

Wild berry extract may strengthen effectiveness of pancreatic cancer drug
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals experimental research published online in the Journal of Clinical Pathology. (2014-09-17)

Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results. (2004-06-05)

New drug regimen shows promising results for treating advanced biliary-tract cancers
Bevacizumab given in addition to the combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) is well tolerated and shows promising antitumour activity in patients with advanced biliary-tract cancers. The survival and tumor response reported in an article published online first in the Lancet Oncology compare favourably with previous studies in patients treated with GEMOX alone and require further investigation in randomized trials. (2009-11-22)

Clinical trial looks to improve pancreatic cancer survival rates
Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates. (2013-02-12)

UCLA cancer scientists identify liposarcoma tumors that respond to chemotherapy
Using a strategy that tracks cancer cells' consumption of nucleosides, a team of researchers at UCLA's Jonsson Comprehensive Center has identified a group of liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC. Furthermore, they have found that these tumors are sensitive to chemotherapy. (2012-12-10)

Page 2 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to